ONK Therapeutics Revenue and Competitors

Galway,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ONK Therapeutics's estimated annual revenue is currently $7.4M per year.(i)
  • ONK Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • ONK Therapeutics has 48 Employees.(i)
  • ONK Therapeutics grew their employee count by 9% last year.

ONK Therapeutics's People

NameTitleEmail/Phone
1
Founder, Advisor and Member BoardReveal Email/Phone
2
CEOReveal Email/Phone
3
Head Process DevelopmentReveal Email/Phone
4
Head ManufacturingReveal Email/Phone
5
Chief Scientific OfficerReveal Email/Phone
6
Founder and Chief Scientific OfficerReveal Email/Phone
7
Chief Operating OfficerReveal Email/Phone
8
R&D Project ManagerReveal Email/Phone
9
R&D Program ManagerReveal Email/Phone
10
Finance ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is ONK Therapeutics?

ONK Therapeutics, is an innovative cell therapy company dedicated to developing a next generation of off-the-shelf, dual-targeted NK cell therapy platform targeting solid and hematological cancers. The Company was founded in 2015, by Prof. O'Dwyer MD, of NUI Galway, an expert in translational multiple myeloma research, the tumour microenvironment, and exploitation of NK cells as cellular immunotherapy. Its core proprietary platform is based on a dual-targeted NK cell expressing both a chimeric antigen receptor (CAR) targeting a known tumour antigen and a TNF related apoptosis inducing ligand variant (TRAILv) targeting the death receptor pathway (i.e. DR4 or DR5). This promising new approach has the potential to enhance efficacy by addressing both intrinsic (e.g. CAR engagement of a tumor specific antigen) and extrinsic (e.g. signalling through the death receptor pathway) apoptotic pathways, and to reduce the susceptibility to possible target antigen escape through the engagement of tumor antigen independent TRAILv.

keywords:N/A

N/A

Total Funding

48

Number of Employees

$7.4M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ONK Therapeutics News

2022-02-22 - Intellia and ONK Therapeutics Enter Gene-Editing Partnership

Intellia Therapeutics, a gene-editing company, and ONK Therapeutics, a company developing natural killer (NK) cell therapies in oncology,...

2022-02-22 - Intellia and ONK Therapeutics Announce Collaboration to Advance ...

ONK Therapeutics is an innovative cell therapy company dedicated to developing the next generation of optimally engineered, off-the-shelf,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.4M5237%N/A
#2
N/A5724%N/A
#3
$7.4M578%N/A
#4
$5.1M5730%N/A
#5
$5.3M58-2%N/A